1. Home
  2. IDN vs CING Comparison

IDN vs CING Comparison

Compare IDN & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

HOLD

Current Price

$5.37

Market Cap

103.0M

Sector

Technology

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$7.17

Market Cap

93.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDN
CING
Founded
1994
2012
Country
United States
United States
Employees
N/A
13
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.0M
93.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
IDN
CING
Price
$5.37
$7.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$7.33
$37.00
AVG Volume (30 Days)
96.2K
563.8K
Earning Date
03-19-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
220.00
N/A
EPS
0.06
N/A
Revenue
$4,433,454.00
N/A
Revenue This Year
$12.21
N/A
Revenue Next Year
$12.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.21
N/A
52 Week Low
$2.30
$3.20
52 Week High
$7.48
$11.89

Technical Indicators

Market Signals
Indicator
IDN
CING
Relative Strength Index (RSI) 61.49 48.32
Support Level $5.12 $3.77
Resistance Level $5.74 $7.92
Average True Range (ATR) 0.27 1.06
MACD 0.08 -0.04
Stochastic Oscillator 51.59 17.71

Price Performance

Historical Comparison
IDN
CING

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: